AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval

AbbVie NYSE:ABBV, the immunology and neuroscience drugmaker, secured FDA approval for Juvmo, a once-daily Parkinson's treatment. Its shares dropped nearly 0.8% to $264.29 at 10.10 EST time on Tuesday, September 29. The approval gives AbbVie a new product to launch, but the small stock move suggests…